These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 23615508)
21. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Fakhouri F; Frémeaux-Bacchi V; Loirat C Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030 [TBL] [Abstract][Full Text] [Related]
22. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679 [TBL] [Abstract][Full Text] [Related]
23. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. Roos A; Rastaldi MP; Calvaresi N; Oortwijn BD; Schlagwein N; van Gijlswijk-Janssen DJ; Stahl GL; Matsushita M; Fujita T; van Kooten C; Daha MR J Am Soc Nephrol; 2006 Jun; 17(6):1724-34. PubMed ID: 16687629 [TBL] [Abstract][Full Text] [Related]
24. The role of the complement system in acute kidney injury. McCullough JW; Renner B; Thurman JM Semin Nephrol; 2013 Nov; 33(6):543-56. PubMed ID: 24161039 [TBL] [Abstract][Full Text] [Related]
25. Role of complement in innate and autoimmunity. Seelen MA; Roos A; Daha MR J Nephrol; 2005; 18(6):642-53. PubMed ID: 16358221 [TBL] [Abstract][Full Text] [Related]
26. Immunopathology of the end-stage kidney. Immunoglobulin and complement component deposition in nonimmune disease. Velosa J; Miller K; Michael AF Am J Pathol; 1976 Jul; 84(1):149-62. PubMed ID: 779494 [TBL] [Abstract][Full Text] [Related]
27. Chemical Approaches to Modulating Complement-Mediated Diseases. Iyer A; Xu W; Reid RC; Fairlie DP J Med Chem; 2018 Apr; 61(8):3253-3276. PubMed ID: 28977749 [TBL] [Abstract][Full Text] [Related]
28. Overview of complement activation and regulation. Noris M; Remuzzi G Semin Nephrol; 2013 Nov; 33(6):479-92. PubMed ID: 24161035 [TBL] [Abstract][Full Text] [Related]
29. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Mastellos DC; Reis ES; Yancopoulou D; Hajishengallis G; Ricklin D; Lambris JD Immunobiology; 2016 Oct; 221(10):1046-57. PubMed ID: 27353192 [TBL] [Abstract][Full Text] [Related]
30. Is complement a target for therapy in renal disease? Mathieson PW Kidney Int; 1998 Nov; 54(5):1429-36. PubMed ID: 9844118 [TBL] [Abstract][Full Text] [Related]
31. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Floege J Am J Kidney Dis; 2011 Dec; 58(6):992-1004. PubMed ID: 21872377 [TBL] [Abstract][Full Text] [Related]
32. The role of complement in autoimmune renal disease. Seelen MA; Daha MR Autoimmunity; 2006 Aug; 39(5):411-5. PubMed ID: 16923541 [TBL] [Abstract][Full Text] [Related]
33. The role of complement in C3 glomerulopathy. Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733 [TBL] [Abstract][Full Text] [Related]
34. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Nester CM; Brophy PD Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421 [TBL] [Abstract][Full Text] [Related]
36. Involvement of complement components in renal disease. Johnson RJ Curr Opin Nephrol Hypertens; 1997 Mar; 6(2):120-7. PubMed ID: 9146972 [TBL] [Abstract][Full Text] [Related]
37. Ex Vivo Complement Activation on Endothelial Cells: Research and Translational Value. Meuleman MS; Fremeaux-Bacchi V; Roumenina LT; Chauvet S Trends Mol Med; 2021 May; 27(5):418-421. PubMed ID: 33648869 [TBL] [Abstract][Full Text] [Related]
38. Complement depletion abolishes IgA-mediated glomerular inflammation in rats. Stad RK; van Gijlswijk-Janssen DJ; van Es LA; Daha MR Exp Nephrol; 1994; 2(3):182-9. PubMed ID: 7922271 [TBL] [Abstract][Full Text] [Related]
39. C3, C4, factor B and HLA-DR alpha mRNA expression in renal biopsy specimens from patients with IgA nephropathy. Oren R; Laufer J; Goldberg I; Kopolovic J; Waldherr R; Passwell JH Immunology; 1995 Dec; 86(4):575-83. PubMed ID: 8567024 [TBL] [Abstract][Full Text] [Related]